Zeyu Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zeyu Wu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jin Zhao
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University), China
4 shared publications Jie Song
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University)
2 shared publicationsMingqi Liu
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University)
2 shared publicationsYizinigaer Yasen
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University)
2 shared publications- Chao Shan
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University), No. 137 South Liyushan Road, Urumqi 830054, PR China; Stomatology Disease Institute of Xinjiang Uyghur Autonomous Region, No.137. South Liyushan Road, Urumqi 830054, PR China
1 shared publication Hongzhao Ding
Department of Cariology and Endodontics, The First Affiliated Hospital of Xinjiang Medical University (The Affiliated Stomatology Hospital of Xinjiang Medical University)
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1899522
Optimization strategies for antimicrobial peptides in dental caries prevention and management: from emerging mechanisms of action to clinical translation
Dental caries remains a prevalent global health burden driven by dysbiosis of the biofilm microbiome. Antimicrobial peptides (AMPs), characterized by a low risk of resistance development and immunomodulatory potential, have emerged as promising alternatives to conventional antimicrobials; however, their clinical translation is still constrained by physiological instability, cytotoxicity, limited oral substantivity, and substantial regulatory and economic barriers. This review systematically summarizes recent advances in the mechanisms of action, rational design, and translational strategies of AMPs for the prevention and management of dental caries. The article first outlines updated mechanistic concepts, highlighting a shift from the classical stable pore-forming model toward transient water channel formation and lipid flip-flop models, and further discusses microbiome-oriented ecological modulation strategies aimed at preserving beneficial commensals and suppressing cariogenic dysbiosis. In addition, structure–activity relationships are examined in depth, with emphasis on how diverse optimization approaches can balance peptide activity, toxicity, stability, selectivity, and manufacturability. The review also delineates the major barriers that impede clinical translation, including production cost, GMP-compatible manufacturing, batch consistency, delivery format, and regulatory definability. Potential strategies are discussed, including molecular farming in plant bioreactors, recombinant or synthetic production platforms, covalent immobilization, in situ biomimetic systems, and pH-responsive delivery systems for improving local bioavailability within cariogenic microenvironments. Finally, we emphasize that most current evidence remains preclinical and that no generalizable clinical framework for AMP-based caries prevention has yet been established. Future development should integrate mechanism-guided design, microbiome-level evaluation, standardized safety and efficacy endpoints, scalable manufacturing, and controlled clinical validation.
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1899522
Open AccessOptimization strategies for antimicrobial peptides in dental caries prevention and management: from emerging mechanisms of action to clinical translation
Dental caries remains a prevalent global health burden driven by dysbiosis of the biofilm microbiome. Antimicrobial peptides (AMPs), characterized by a low risk of resistance development and immunomodulatory potential, have emerged as promising alternatives to conventional antimicrobials; however, their clinical translation is still constrained by physiological instability, cytotoxicity, limited oral substantivity, and substantial regulatory and economic barriers. This review systematically summarizes recent advances in the mechanisms of action, rational design, and translational strategies of AMPs for the prevention and management of dental caries. The article first outlines updated mechanistic concepts, highlighting a shift from the classical stable pore-forming model toward transient water channel formation and lipid flip-flop models, and further discusses microbiome-oriented ecological modulation strategies aimed at preserving beneficial commensals and suppressing cariogenic dysbiosis. In addition, structure–activity relationships are examined in depth, with emphasis on how diverse optimization approaches can balance peptide activity, toxicity, stability, selectivity, and manufacturability. The review also delineates the major barriers that impede clinical translation, including production cost, GMP-compatible manufacturing, batch consistency, delivery format, and regulatory definability. Potential strategies are discussed, including molecular farming in plant bioreactors, recombinant or synthetic production platforms, covalent immobilization, in situ biomimetic systems, and pH-responsive delivery systems for improving local bioavailability within cariogenic microenvironments. Finally, we emphasize that most current evidence remains preclinical and that no generalizable clinical framework for AMP-based caries prevention has yet been established. Future development should integrate mechanism-guided design, microbiome-level evaluation, standardized safety and efficacy endpoints, scalable manufacturing, and controlled clinical validation.
- Open Access
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1759697
Ethnopharmacology, phytochemistry, and pharmacology of sea buckthorn (Hippophae rhamnoides L.): a comprehensive review
This review provides a comprehensive synthesis of the ethnopharmacological uses, modern applications, phytochemistry, and pharmacological mechanisms of Hippophae rhamnoides L . ( H. rhamnoides ) It begins by detailing its foundational role in traditional medical systems within its native range, including Tibetan, Mongolian, and Chinese medicine, as well as its broader Eurasian ethnobotanical applications. The work then systematically outlines the plant’s diverse modern utilizations in nutraceuticals, cosmeceuticals, pharmaceuticals, and environmental remediation. A thorough organ-specific analysis of its phytochemical architecture that identifies key bioactive constituents in berries, seeds and leaves links to demonstrated pharmacological effects, including hepatoprotective, anti-inflammatory, cardioprotective and neuroprotective activities. A critical discussion on the potential interference of Pan-Assay Interference Compounds (PAINS) is included to provide a necessary caveat for interpreting bioactivity data. Finally, the review identifies persistent challenges including phytochemical standardization and the translational gap between preclinical and clinical research, and proposes future research directions focused on rigorous clinical trials, mechanistic studies and sustainable exploitation within a circular bioeconomy framework.
- 6 March 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1759697
Open AccessEthnopharmacology, phytochemistry, and pharmacology of sea buckthorn (Hippophae rhamnoides L.): a comprehensive review
This review provides a comprehensive synthesis of the ethnopharmacological uses, modern applications, phytochemistry, and pharmacological mechanisms of Hippophae rhamnoides L . ( H. rhamnoides ) It begins by detailing its foundational role in traditional medical systems within its native range, including Tibetan, Mongolian, and Chinese medicine, as well as its broader Eurasian ethnobotanical applications. The work then systematically outlines the plant’s diverse modern utilizations in nutraceuticals, cosmeceuticals, pharmaceuticals, and environmental remediation. A thorough organ-specific analysis of its phytochemical architecture that identifies key bioactive constituents in berries, seeds and leaves links to demonstrated pharmacological effects, including hepatoprotective, anti-inflammatory, cardioprotective and neuroprotective activities. A critical discussion on the potential interference of Pan-Assay Interference Compounds (PAINS) is included to provide a necessary caveat for interpreting bioactivity data. Finally, the review identifies persistent challenges including phytochemical standardization and the translational gap between preclinical and clinical research, and proposes future research directions focused on rigorous clinical trials, mechanistic studies and sustainable exploitation within a circular bioeconomy framework.
- Open Access
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1722083
Naringin as a non-antibiotic agent for multi-species oral biofilm control: in vitro antimicrobial mechanisms and in vivo safety in a rat caries model
Introduction: Dental caries is driven by dysbiosis of oral biofilms. Conventional antibiotics easily disrupt oral commensal balance, creating an urgent need for natural, non-antibiotic agents that can target cariogenic biofilms without causing ecological collapse. Methods: The antimicrobial and antibiofilm efficacy of Naringin was evaluated in vitro against planktonic and biofilm states of Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguinis (mono-species), and their multi-species consortium. Minimum inhibitory/bactericidal concentrations (MIC/MBC) and minimum biofilm inhibitory/reduction concentrations (MBIC/MBRC) were determined. Effects on acid production, extracellular polysaccharide (EPS) synthesis, and bacterial adhesion to hydroxyapatite (HAP) were mechanistically investigated. In vivo , a rat caries model induced by the multi-species consortium was topically treated with Naringin (2 × MIC, MIC, 1/2 × MIC) for 4 weeks. Caries lesions were evaluated using Keyes scoring and micro-computed tomography. Oral microbiota, serum biochemistry, and histopathology were analyzed for safety assessment. Results: Naringin exhibited potent, concentration-dependent antimicrobial activity. MICs were 1.00 mg/mL for S. mutans and S. sanguinis , 0.50 mg/mL for S. sobrinus , and 0.50 mg/mL for the multi-species consortium. Naringin at MBIC (2 mg/mL for multi-species) significantly disrupted biofilm architecture, reduced viable bacteria, and inhibited EPS synthesis. It maintained biofilm pH above 5.5 (the critical threshold for enamel demineralization), inhibited lactate production, and reduced multi-species bacterial adhesion to HAP by 68.3% at MIC. In vivo , Naringin (MIC) significantly reduced Keyes scores on smooth and sulcal surfaces by over 60%, preserved enamel integrity, and rebalanced the oral microbiota without inducing mucosal irritation or systemic toxicity. Discussion: Naringin, a natural non-antibiotic agent, effectively inhibits the “adhesion-biofilm-acid-EPS” cascade of multi-species cariogenic biofilms. Its selective efficacy against pathogens and favorable in vivo safety profile position it as a promising ecological agent for caries prevention by addressing oral dysbiosis at its root.
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 16, 1722083
Open AccessNaringin as a non-antibiotic agent for multi-species oral biofilm control: in vitro antimicrobial mechanisms and in vivo safety in a rat caries model
Introduction: Dental caries is driven by dysbiosis of oral biofilms. Conventional antibiotics easily disrupt oral commensal balance, creating an urgent need for natural, non-antibiotic agents that can target cariogenic biofilms without causing ecological collapse. Methods: The antimicrobial and antibiofilm efficacy of Naringin was evaluated in vitro against planktonic and biofilm states of Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguinis (mono-species), and their multi-species consortium. Minimum inhibitory/bactericidal concentrations (MIC/MBC) and minimum biofilm inhibitory/reduction concentrations (MBIC/MBRC) were determined. Effects on acid production, extracellular polysaccharide (EPS) synthesis, and bacterial adhesion to hydroxyapatite (HAP) were mechanistically investigated. In vivo , a rat caries model induced by the multi-species consortium was topically treated with Naringin (2 × MIC, MIC, 1/2 × MIC) for 4 weeks. Caries lesions were evaluated using Keyes scoring and micro-computed tomography. Oral microbiota, serum biochemistry, and histopathology were analyzed for safety assessment. Results: Naringin exhibited potent, concentration-dependent antimicrobial activity. MICs were 1.00 mg/mL for S. mutans and S. sanguinis , 0.50 mg/mL for S. sobrinus , and 0.50 mg/mL for the multi-species consortium. Naringin at MBIC (2 mg/mL for multi-species) significantly disrupted biofilm architecture, reduced viable bacteria, and inhibited EPS synthesis. It maintained biofilm pH above 5.5 (the critical threshold for enamel demineralization), inhibited lactate production, and reduced multi-species bacterial adhesion to HAP by 68.3% at MIC. In vivo , Naringin (MIC) significantly reduced Keyes scores on smooth and sulcal surfaces by over 60%, preserved enamel integrity, and rebalanced the oral microbiota without inducing mucosal irritation or systemic toxicity. Discussion: Naringin, a natural non-antibiotic agent, effectively inhibits the “adhesion-biofilm-acid-EPS” cascade of multi-species cariogenic biofilms. Its selective efficacy against pathogens and favorable in vivo safety profile position it as a promising ecological agent for caries prevention by addressing oral dysbiosis at its root.
- Open Access
- 20 November 2025
- Published by Elsevier in Archives of Oral Biology
- Vol. 182, 106459
Tetramethoxyluteolin, an active constituent in mulberry leaves, promotes osteogenesis of jaw bone marrow mesenchymal stem cells in periodontitis microenvironment via NF-κB inhibition
- 20 November 2025
- Published by Elsevier in Archives of Oral Biology
- Vol. 182, 106459
Open AccessTetramethoxyluteolin, an active constituent in mulberry leaves, promotes osteogenesis of jaw bone marrow mesenchymal stem cells in periodontitis microenvironment via NF-κB inhibition